Pump design could give new hope to heart patients

Apr 12, 2007

A new counter-flow heart pump being developed by Queensland University of Technology has the potential to revolutionise future designs of the mechanical heart. Lead researcher Associate Professor Andy Tan said the heart pump's innovative design was based on a doubleoutput centrifugal model that pushed the blood in a counter direction to ensure correct flow through both sides of the heart, and is the subject of a patent application.

"The counter-flow pump is a bi-ventricular assist device (BVAD), meaning it supports both the left and right sides of the heart simultaneously," he said. "But what's so groundbreaking is that it is the first device to combine the function of two pumps into one unit. Professor Tan said current double heart pump technology was too bulky because it required the implant of two pumps that worked independently.

"The problem with two pumps is that it requires different controllers and can potentially lead to an uneven blood flow.

"The concept of the counter-flow pump is that it has two independent impellers to simulate two pumps to augment the operations of the left and right ventricles but is essential only one. "Using independent impellers, the blood is able to flow at a higher delivery pressure as required by the left chamber of the heart, and a slower pressure as required by the right chamber of the heart."

Professor Tan said a shortage of heart donors and high rates of cardiovascular disease were driving scientists across the globe to develop the technology for a replacement heart. "Each year in Australia, 44 per cent of all deaths are related to heart disease," Professor Tan said. "In fact heart failure, stroke and vascular disease kill more Australians than any other disease group. To reduce the number of deaths, treatment is now focused on medical devices that can assist or totally replicate the function of the heart."

He said a heart pump capable of supporting both chambers would dramatically increase patients' chance of survival. "Clinical studies around the world have found that patients who received a permanent left heart pump (left ventricular assist device) reduced their risk of dying within one year by 47 per cent," Professor Tan said. "Unfortunately 25 per cent of these patients went on to develop right heart failure syndrome, infection and multiorgan failure. We have developed the design, and computer modelling has shown that it works."

Source: Queensland University of Technology

Explore further: Researchers pinpoint how smoking causes osteoporosis

add to favorites email to friend print save as pdf

Related Stories

Research examines how technology can break down barriers

26 minutes ago

A small, pilot study is examining how mobile technology might support deaf and hard-of-hearing college students when an interpreter can't physically be present at the time the services are requested. The University of Cincinnati ...

First risk assessment of shale gas fracking to biodiversity

59 minutes ago

Fracking, the controversial method of mining shale gas, is widespread across Pennsylvania, covering up to 280,000 km² of the Appalachian Basin. New research in the Annals of the New York Academy of Sciences explores the th ...

Recommended for you

Researcher studies protein's link to heart disease

Jun 18, 2013

(Medical Xpress)—The largest protein known to exist in the human body functions as a molecular spring, and University of Arizona researchers are gaining new insights into its role in heart disease.

The rhythm of everything

Jun 18, 2013

Dawn triggers basic biological changes in the waking human body. As the sun rises, so does heart rate, blood pressure and body temperature. The liver, the kidneys and many natural processes also begin shifting ...

User comments : 0

More news stories

No danger of cancer through gene therapy virus

In fall 2012, the European Medicines Agency (EMA) approved the modified adeno-associated virus AAV-LPL S447X as the first ever gene therapy for clinical use in the Western world. uniQure, a Dutch biotech company, had developed ...

Antioxidant shows promise in Parkinson's disease

Diapocynin, a synthetic molecule derived from a naturally occurring compound (apocynin), has been found to protect neurobehavioral function in mice with Parkinson's Disease symptoms by preventing deficits in motor coordination.

Paralysed with fear: The story of polio

Thanks to vaccination, polio has been pushed to the brink of extinction – but can we finish the job? This is one of the big questions which a Bristol academic addresses in his new book, published next week.

EUROnu project recommends building Neutrino Factory

(Phys.org) —The European Union's Seventh Framework Programme, EUROnu, has submitted its findings to a panel at CERN. Charged with choosing a project to study the nature of matter and antimatter, the project ...